iifl-logo

Aarti Drugs Ltd Quarterly Results

418.65
(0.22%)
May 9, 2025|12:00:00 AM

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Financials

Particulars (Rupees in Crores.)Mar-2025Dec-2024Sept-2024Jun-2024Mar-2024

Gross Sales

676.76

556.6

598.33

555.34

619.99

Excise Duty

0

0

0

0

0

Net Sales

676.76

556.6

598.33

555.34

619.99

Other Operating Income

0

0

0

0

0

Other Income

1.87

11.9

1.48

1.11

1.08

Total Income

678.63

568.5

599.81

556.45

621.07

Total Expenditure

583.43

494.88

531.28

490.38

534.18

PBIDT

95.2

73.62

68.53

66.07

86.89

Interest

9.16

9.07

8.93

8.71

9.13

PBDT

86.04

64.55

59.6

57.36

77.76

Depreciation

14.88

13.8

13.72

13.38

13.58

Minority Interest Before NP

0

0

0

0

0

Tax

10.37

12

8.79

10.02

15.1

Deferred Tax

-1.98

1.66

2.13

0.69

1.77

Reported Profit After Tax

62.77

37.09

34.96

33.27

47.31

Minority Interest After NP

-0.09

0.04

-0.05

0.03

-0.06

Net Profit after Minority Interest

62.86

37.05

35.01

33.24

47.37

Extra-ordinary Items

0

0

0

0

0

Adjusted Profit After Extra-ordinary item

62.86

37.05

35.01

33.24

47.37

EPS (Unit Curr.)

6.88

4.06

3.83

3.62

5.15

Book Value (Unit Curr.)

0

0

0

0

0

Dividend (%)

0

10

0

0

0

Equity

91.27

91.27

91.27

91.94

91.94

Public Shareholding (Number)

0

0

0

0

0

Public Shareholding (%)

0

0

0

0

0

Pledged/Encumbered - No. of Shares

0

0

0

0

0

Pledged/Encumbered - % in Total Promoters Holding

0

0

0

0

0

Pledged/Encumbered - % in Total Equity

0

0

0

0

0

Non Encumbered - No. of Shares

0

0

0

0

0

Non Encumbered - % in Total Promoters Holding

0

0

0

0

0

Non Encumbered - % in Total Equity

0

0

0

0

0

PBIDTM(%)

14.06

13.22

11.45

11.89

14.01

PBDTM(%)

12.71

11.59

9.96

10.32

12.54

PATM(%)

9.27

6.66

5.84

5.99

7.63

Aarti Drugs: Related NEWS

Aarti Drugs Q3 Profit Up 1%, Revenue Drops 8% YoY
30 Jan 2025|10:25 PM

The consolidated net profit of the company increased 1.1% YoY at ₹37.1 crore from ₹36.7 crore that was reported for the same quarter last year.

Read More
Aarti Drugs Tarapur Facility Gets US FDA Clearance
26 Dec 2024|11:48 PM

Aarti Drugs shares has witnessed a 8% dip in the last one year, and 10% dip in the last six months.

Read More
Top 10 stocks for today - 4th October, 2024
4 Oct 2024|08:46 AM

Here are some of the stocks that may see significant price movement today: Avenue Supermarts, Bank of Baroda, HDFC Bank, etc.

Read More
Top 10 stocks for today – 23rd September 2024
23 Sep 2024|09:34 AM

Here are some of the stocks that may see significant price movement today: HFCL, Aster DM Healthcare, Tata Steel, Glenmark Pharma, etc.

Read More

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2025, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited (Formerly known as IIFL Securities Ltd). All rights Reserved.

IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)

ISO certification icon
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.